S&P 500   3,116.13 (-0.13%)
DOW   27,851.08 (-0.30%)
QQQ   203.14 (-0.11%)
BABA   182.94 (-1.25%)
T   36.94 (-2.79%)
BAC   32.72 (-0.67%)
S&P 500   3,116.13 (-0.13%)
DOW   27,851.08 (-0.30%)
QQQ   203.14 (-0.11%)
BABA   182.94 (-1.25%)
T   36.94 (-2.79%)
BAC   32.72 (-0.67%)
S&P 500   3,116.13 (-0.13%)
DOW   27,851.08 (-0.30%)
QQQ   203.14 (-0.11%)
BABA   182.94 (-1.25%)
T   36.94 (-2.79%)
BAC   32.72 (-0.67%)
S&P 500   3,116.13 (-0.13%)
DOW   27,851.08 (-0.30%)
QQQ   203.14 (-0.11%)
BABA   182.94 (-1.25%)
T   36.94 (-2.79%)
BAC   32.72 (-0.67%)
Log in

Novo Nordisk A/S Stock Price, Forecast & Analysis (NYSE:NVO)

$54.62
-2.42 (-4.24 %)
(As of 11/20/2019 11:13 AM ET)
Today's Range
$54.43
Now: $54.62
$55.87
50-Day Range
$49.69
MA: $54.15
$57.91
52-Week Range
$43.57
Now: $54.62
$58.01
Volume120,432 shs
Average Volume1.41 million shs
Market Capitalization$129.34 billion
P/E Ratio21.67
Dividend Yield1.11%
Beta0.61
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone45-4444-8888

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$17.72 billion
Cash Flow$2.62 per share
Book Value$3.24 per share

Profitability

Net Income$5.91 billion

Miscellaneous

Employees43,202
Outstanding Shares2,368,000,000
Market Cap$129.34 billion
Next Earnings Date2/7/2020 (Estimated)
OptionableOptionable

Receive NVO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.


Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S declared a Semi-Annual dividend on Friday, August 9th. Investors of record on Monday, August 19th will be paid a dividend of $0.318 per share on Tuesday, August 27th. The ex-dividend date is Friday, August 16th. View Novo Nordisk A/S's Dividend History.

How will Novo Nordisk A/S's stock buyback program work?

Novo Nordisk A/S announced that its Board of Directors has approved a stock repurchase program on Friday, February 2nd 2018, which authorizes the company to buyback outstanding shares, according to EventVestor. This buyback authorization authorizes the company to buy shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company's management believes its stock is undervalued.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) posted its earnings results on Friday, November, 1st. The company reported $0.64 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.62 by $0.02. The company earned $4.51 billion during the quarter, compared to analyst estimates of $4.55 billion. Novo Nordisk A/S had a return on equity of 75.48% and a net margin of 32.44%. View Novo Nordisk A/S's Earnings History.

When is Novo Nordisk A/S's next earnings date?

Novo Nordisk A/S is scheduled to release their next quarterly earnings announcement on Friday, February 7th 2020. View Earnings Estimates for Novo Nordisk A/S.

What price target have analysts set for NVO?

13 equities research analysts have issued 1 year price targets for Novo Nordisk A/S's stock. Their forecasts range from $48.61 to $400.00. On average, they expect Novo Nordisk A/S's share price to reach $181.58 in the next year. This suggests a possible upside of 229.7% from the stock's current price. View Analyst Price Targets for Novo Nordisk A/S.

What is the consensus analysts' recommendation for Novo Nordisk A/S?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 2 sell ratings, 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novo Nordisk A/S.

Has Novo Nordisk A/S been receiving favorable news coverage?

Media coverage about NVO stock has been trending somewhat negative recently, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Novo Nordisk A/S earned a daily sentiment score of -1.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Novo Nordisk A/S.

Are investors shorting Novo Nordisk A/S?

Novo Nordisk A/S saw a drop in short interest in the month of October. As of October 31st, there was short interest totalling 6,570,000 shares, a drop of 8.6% from the September 30th total of 7,190,000 shares. Based on an average trading volume of 1,370,000 shares, the days-to-cover ratio is presently 4.8 days. Approximately 0.4% of the company's shares are short sold. View Novo Nordisk A/S's Current Options Chain.

Who are some of Novo Nordisk A/S's key competitors?

What other stocks do shareholders of Novo Nordisk A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), Pfizer (PFE), AbbVie (ABBV), Johnson & Johnson (JNJ), Celgene (CELG), QUALCOMM (QCOM), Cisco Systems (CSCO), Walt Disney (DIS), Starbucks (SBUX) and AT&T (T).

Who are Novo Nordisk A/S's key executives?

Novo Nordisk A/S's management team includes the folowing people:
  • Mr. Lars Fruergaard Jørgensen, Pres & CEO (Age 53)
  • Dr. Mads Krogsgaard Thomsen, Exec. VP & Chief Science Officer (Age 59)
  • Mr. Karsten Munk Knudsen, Exec. VP & CFO (Age 47)
  • Mr. Lars Green, Exec. VP and Head of Bus. Services & Compliance (Age 52)
  • Mr. Ole F. Ramsby, Sr. VP & Gen. Counsel of Legal Affairs

Who are Novo Nordisk A/S's major shareholders?

Novo Nordisk A/S's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.64%), Everett Harris & Co. CA (0.13%), Saratoga Research & Investment Management (0.07%), Envestnet Asset Management Inc. (0.04%), Russell Investments Group Ltd. (0.02%) and Parsec Financial Management Inc. (0.02%). View Institutional Ownership Trends for Novo Nordisk A/S.

Which major investors are selling Novo Nordisk A/S stock?

NVO stock was sold by a variety of institutional investors in the last quarter, including BB&T Securities LLC, Ledyard National Bank, Arlington Partners LLC, Scout Investments Inc., Carillon Tower Advisers Inc., Crossmark Global Holdings Inc., Baldwin Brothers Inc. MA and BBVA USA Bancshares Inc.. View Insider Buying and Selling for Novo Nordisk A/S.

Which major investors are buying Novo Nordisk A/S stock?

NVO stock was bought by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, QV Investors Inc., Kornitzer Capital Management Inc. KS, Envestnet Asset Management Inc., Janney Montgomery Scott LLC, Oppenheimer Asset Management Inc., Eagle Asset Management Inc. and Beacon Investment Advisory Services Inc.. View Insider Buying and Selling for Novo Nordisk A/S.

How do I buy shares of Novo Nordisk A/S?

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Novo Nordisk A/S's stock price today?

One share of NVO stock can currently be purchased for approximately $55.07.

How big of a company is Novo Nordisk A/S?

Novo Nordisk A/S has a market capitalization of $130.41 billion and generates $17.72 billion in revenue each year. The company earns $5.91 billion in net income (profit) each year or $2.52 on an earnings per share basis. Novo Nordisk A/S employs 43,202 workers across the globe.View Additional Information About Novo Nordisk A/S.

What is Novo Nordisk A/S's official website?

The official website for Novo Nordisk A/S is http://www.novonordisk.com/.

How can I contact Novo Nordisk A/S?

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]


MarketBeat Community Rating for Novo Nordisk A/S (NYSE NVO)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  325 (Vote Outperform)
Underperform Votes:  421 (Vote Underperform)
Total Votes:  746
MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote "Outperform" if you believe NVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel